Clinical advances in epigenetic therapies for lymphoma

Clinical Epigenetics

Table 2 Summary of select grade ≥ 3 AEs by epigenetic therapy class

Epigenetic class	Agent	Indication	Grade ≥ 3 AE, incidence (%)
DNMT inhibitor	Azacitidine + vorinostat + chemotherapy	NHL, HL, TCL [32]	Mucositis (32), neutropenic fever (100), transient hyperbilirubinemia (18), transaminase elevation (25)
EZH2 inhibitor	Tazemetostat	FL [33]	Anemia (2), neutropenia (3), thrombocytopenia (3)
EZH2 inhibitor	Valemetostat	NHL, TCL [38]	Pneumonia (7), anemia,^a dysgeusia,^a decreased platelet count^a
PRMT5 inhibitor	JNJ-64619178	NHL [73]	Anemia (17), neutropenia (6), thrombocytopenia (20)
HDAC inhibitor	Vorinostat	NHL [34, 35, 74]	Anemia (4–6), decreased platelet count (29), neutropenia (41), thrombocytopenia (6–48)
	Vorinostat	CTCL [39, 75]	Anemia (1–8), fatigue (5), thrombocytopenia (5–19)
	Abexinostat	NHL, TCL [76]	Anemia (12), neutropenia (27), thrombocytopenia (80)
	Panobinostat	CTCL [77, 78]	Thrombocytopenia (17–20), neutropenia (9–20)
	Fimepinostat	DLBCL [79]	Neutropenia (16), thrombocytopenia (36)
	Romidepsin	CTCL, PTCL [40, 100,101,102]	Neutropenia (0–18), thrombocytopenia (0–23), lymphopenia (0–21), leukopenia (0–12)
BET inhibitor	Molibresib	NHL [80]	Thrombocytopenia (70)

BET bromodomain and extraterminal domain; CTCL cutaneous T cell lymphoma; DLBCL diffuse large B cell lymphoma; DMNT DNA N-methyltransferase; EZH2 enhancer of zeste homolog 2; FL follicular lymphoma; HDAC histone deacetylase; HL Hodgkin lymphoma; NHL non-Hodgkin lymphoma; PTCL peripheral T cell lymphoma, PRMT protein arginine methyltransferase; and TCL T cell lymphoma
^aAdverse events not listed by grade

ISSN: 1868-7083